Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data

Bioanalysis

Volumn 2, Issue 3, 2010, Pages 429-440

  Garner, R Colin ^a,b  

^a Xceleron Ltd   (United Kingdom)

^b Garner Consulting Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CARBON 14; CLARITHROMYCIN; DIAZEPAM; DIPHENHYDRAMINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; MIDAZOLAM; PARACETAMOL; PHENOBARBITAL; PROPAFENONE; SUMATRIPTAN; UNCLASSIFIED DRUG; WARFARIN; XENOBIOTIC AGENT; ZIDOVUDINE; ZK 253; DRUG;

ACCELERATOR MASS SPECTROMETRY; AREA UNDER THE CURVE; BINDING AFFINITY; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFORMATION; DRUG METABOLISM; DRUG MICRODOSE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN VERSUS ANIMAL COMPARISON; INSOMNIA; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROSTATE HYPERTROPHY; REVIEW; SPECIES DIFFERENCE; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; ANIMAL; METABOLISM; METHODOLOGY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); STATISTICAL MODEL;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LINEAR MODELS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 79952457436     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.6     Document Type: Review

References (38)

1. DiMasi J, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Hlth Economics 22, 151-185 (2003). (Pubitemid 36279392)
2. DiMasi JA, Grabowski HG, Vernon J. R & D costs and returns by therapeutic category. Drug Inf. J. 38, 211-223 (2004). (Pubitemid 39121144)
3. Hopkins A, Groom C. The druggable genome. Nat. Rev. Drug Discov. 1, 727-730 (2002). (Pubitemid 37361545)
4. Betz UAK. How many genomics targets can a portfolio afford. Drug Disc. Today 10, 1057-1063 (2005). (Pubitemid 41074144)
5. van de Waterbeemd H, Gifford E. ADMET in silico modeling: towards prediction paradise. Nat. Rev. Drug Disc. 2, 192-204 (2003). (Pubitemid 37361664)
6. Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology: the advent of toxicogenomics. Mol. Carcinogenesis 24, 153-159 (1999). (Pubitemid 29169855)
7. Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog and monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Met. Toxicol. 2, 875-894 (2006). (Pubitemid 44911538)
8. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Seminars Cancer Biology 14, 473-486 (2004). (Pubitemid 39360995)
9. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004). (Pubitemid 39173511)
10. Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modeling. Adv. Drug Delivery Rev. 54, 433-451 (2002).
11. Turteltaub KW, Mauthe RJ, Dingley KH et al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutation Res. 376, 243-252 (1997). (Pubitemid 27248608)
12. Mauthe RJ, Dingley KH, Leveson SH et al. Comparison of DNA-adduct and tissue available dose levels of MeIQx in human and rat colon following administration of a very low dose. Int. J. Cancer 80, 539-545 (1999). (Pubitemid 29047518)
13. Cupid BC, Lightfoot TJ, Russell D et al. Formation of AFB1-macromolecular adducts in rats and humans at dietary relevant doses. Food Chem. Toxicol. 42, 559-569 (2003). (Pubitemid 38314826)
14. Garner RC. Accelerating drug development by accelerator mass spectrometry - a new ultrasensitive analytical method. European Pharmaceutical Contractor 22-28 (1999).
15. Garner RC, Leong D. Pushing the accelerator - speeding up drug research with accelerator mass spectrometry. Nucl. Instruments Methods Phys. Res. B 172, 892-898 (2000). (Pubitemid 32067482)
16. Garner RC. Ultrasensitive analysis of isotopes in drug discovery and development using accelerator mass spectrometry. Synthesis and applications of isotopically labelled compounds. Pleiss U, Voges R (Eds). Wiley, London, UK, 503-510 (2001).
17. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2, 233-240 (2003). (Pubitemid 37361669)
18. Smith DA, Johnson D, Park K. Use of microdosing to probe pharmacokinetics in humans - is it too much for too little. Current Opin. Drug Discov. Dev. 6, 39-40 (2003). (Pubitemid 36206937)
19. Boyde RA, Lalonde RL. Non-traditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact. Clin. Pharm. Therap. 81, 24-26 (2007). (Pubitemid 46050861)
20. Bertino JS, Greenberg HE, Reed MD. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 47, 418-422 (2007). (Pubitemid 46465964)
21. Rowland M. Commentary on ACCP position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 47, 1595-1596 (2007). (Pubitemid 350115295)
22. Lappin G, Kuhnz W, Jochemsen R et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Therap. 80, 203-215 (2006). (Pubitemid 44313903)
23. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7, 99-111 (2007). (Pubitemid 46567142)
24. DiMasi JA. The value of improving the productivity of the drug development process. Pharmacoeconomics 20(Suppl. 3), 1-10 (2002).
25. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratidine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 18, 399-411 (2004). (Pubitemid 39215352)
26. Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4, 1499-1506 (2008).
27. le Vuong T, Ruckle JL, Blood AB et al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J. Pharm. Sci. 97, 2833-2843 (2008).
28. Madan A, O'brien Z, Wen J et al. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose. Br. J. Clin. Pharmacol. 67, 288-298 (2009).
29. Position paper on non-clinical safety studies to support clinical trials with a single microdose. EMEA CPMP/SWP/2599/02/ Rev 1, London, UK (2004).
30. Guidance for Industry, Investigators, and Reviewers. Exploratory IND Studies. US FDA. Center for Drug Evaluation and Research, Washington DC, USA (2006).
31. Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. ICH M3 (R2). International Conference on Harmonisation. 11 (2009).
32. Pritchard JF, Jurima-Romet M, Reimer MLJ, Mortimer E, Rolfe B, Cayen MN. Making better drugs: decision gates in non-clinical drug development. Nature Rev. Drug Discov. 2, 542-553 (2003). (Pubitemid 37361746)
33. US FDA. Guidance for industry. Safety testing of drug metabolites. (2008).
34. Sluis-Cremer N, Koontz D, Bassit L et al. Anti-human immunodeficiency virus activity, cross-resistance and intracellular pharmacology of the 3′-azido-2′,3′- dideoxypurine nucleosides. Antimicrob. Agents Chemo. 53, 3715-3719 (2009).
35. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28, 507-532 (2001). (Pubitemid 34289541)
36. Otyepa M, Skopalik J, Anzenbacherova E, Anzenbacher P. What common structural features and variations of mammalian P-450s are known to date? Biochem. Biophys. Acta 1770, 376-389 (2007). (Pubitemid 46136748)
37. Challenge and opportunity on the critical path to new medical products. US FDA, Center for Drug Evaluation and Research, Washington DC, USA (2004).
38. EU Microdose AMS Partnership Programme www.eumapp.com